Cellular Biomedicine Group to Present at Rodman & Renshaw Annual Global Investment Conference

Cellular Biomedicine Group to Present at Rodman & Renshaw Annual Global
Investment Conference

PALO ALTO, Calif., Aug. 27, 2014 (GLOBE NEWSWIRE) -- Cellular Biomedicine
Group Inc. (Nasdaq:CBMG) (the "Company") a biomedicine firm engaged in the
development of new treatments for degenerative and cancerous diseases, today
announced that Dr. William (Wei) Cao, CEO, will be presenting at the Rodman &
Renshaw 16^th Annual Global Investment Conference on Tuesday, September 9 at
4:10 P.M. EDT. The conference is being held September 8-10, 2014 at the New
York Palace Hotel in New York City. A live audio webcast of the presentation
will be available by accessing http://wsw.com/webcast/rrshq24/​.

The Company will discuss the significance of the recently announced
acquisition of immune cell therapy technology, the most recent developments in
its lead therapy candidate ReJoin^TM for Knee Osteoarthritis (KOA) and other
recent pipeline updates.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the
treatment of certain degenerative diseases and cancers. Our developmental stem
cell, progenitor cell, and immune cell projects are the result of research and
development by scientists and doctors fromChinaandthe United States. Our
flagship GMP facility, consisting of eight independent cell production lines,
is designed, certified and managed according to U.S. standards. To learn more
about CBMG, please visit: www.cellbiomedgroup.com

Forward-Looking Statements

Statements in this press release relating to plans, strategies, trends,
specific activities or investments, and other statements that are not
descriptions of historical facts may be forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. Forward-looking information is inherently
subject to risks and uncertainties, and actual results could differ materially
from those currently anticipated due to a number of factors, which include,
but are not limited to, risk factors inherent in doing business.
Forward-looking statements may be identified by terms such as "may," "will,"
"expects," "plans," "intends," "estimates," "potential," or "continue," or
similar terms or the negative of these terms. Although CBMG believes the
expectations reflected in the forward-looking statements are reasonable, they
cannot guarantee that future results, levels of activity, performance or
achievements will be obtained. CBMG does not have any obligation to update
these forward-looking statements other than as required by law.

CONTACT: Sarah Kelly
         Director of Corporate Communications
         +1 650 566-5064
         sarah.kelly@cellbiomedgroup.com
        
         Vivian Chen
         Managing Director Investor Relations, Grayling
         +1 646 284-9427
         vivian.chen@grayling.com

Cellular Biomedicine Group Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.